

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HENLEY et al

Atty. Ref.: 3589-56

Serial No.

Group:

Filed:

Examiner:

For: ELECTROKINETIC DELIVERY OF MEDICAMENTS

* * * * *

March 24, 2004

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. §1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. A copy of each of the references may be found in parent application Serial No. 10/245,337. This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Richard G. Besha
Richard G. Besha
Reg. No. 22,770

RGB:pfc
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	206,474	7/1878	MOREL			
	279,524	06/1883	BEATY	607	145	
	484,522	10/1892	McBRIDE			
	600,290	03/1898	MUIR			
	1,967,927	07/1934	DEUSTCH	604	20	
	2,047,308	07/1936	CHAPMAN	128	799	
	2,123,980	7/1938	WARWICK			
	2,126,070	08/1938	WAPPLER			
	2,834,344	05/1958	KANAI			
	3,019,787	02/1962	SIMMONS			
	3,048,170	08/1962	LEMONS			
	3,107,672	10/1963	HOFMANN			
	3,163,166	12/1964	BRANT ET AL.			
	3,298,368	01/1967	CHAROS	128	260	
	3,520,297	07/1970	BECHTOLD			
	3,556,105	1/1971	SHEPARD			
	3,645,260	02/1972	CINOTTI ET AL.			
	3,716,054	02/1973	PORTER ET AL.			
	3,831,598	08/1974	TICE			
	3,848,600	11/1974	PATRICK, JR. ET AL.	128	783	
	4,116,238	09/1978	PETTIJOHN	128	172.1	
	4,211,222	07/1980	TAPPER	128	803	
	4,292,968	10/1981	ELLIS	128	207.21	
	4,301,794	11/1981	TAPPER	604	20	
	4,325,367	04/1982	TAPPER			
	4,383,529	05/1983	WEBSTER			
	4,393,884	07/1983	JACOBS	131	273	
	4,406,658	09/1983	LATTIN ET AL.	604	20	
	4,416,274	11/1983	JACOBSEN ET AL.	128	803	
	4,429,703	02/1984	HABER	131	273	
	4,474,570	10/1984	ARIURA ET AL.	604	20	
	4,510,939	04/1985	BRENMAN ET AL.	128	639	
	4,639,244	01/1987	RIZK ET AL.			
	4,655,229	04/1987	SENSABAUGH, JR. ET AL.	131	273	
	4,665,921	05/1987	TERANISHI ET AL.			
	4,689,039	08/1987	MASAKI			
	4,702,732	10/1987	POWERS ET AL.			
	4,708,716	11/1987	SIBALIS	604	20	
	4,735,217	04/1988	GERTH ET AL.	131	273	
	4,747,819	05/1988	PHIPPS ET AL.			
*Examiner			Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,756,318	07/1988	CLEARMAN ET AL.	131	359	
	4,763,660	08/1988	KROLL ET AL.	128	798	
	4,764,164	08/1988	SASAKI	604	20	
	4,767,402	08/1988	KOST ET AL.			
	4,771,796	09/1988	MYER	131	273	
	4,776,353	10/1988	LILJA ET AL.	131	297	
	4,786,278	11/1988	MASAKI	604	20	
	4,787,888	11/1988	FOX			
	4,793,366	12/1988	HILL	131	273	
	4,800,903	01/1989	RAY ET AL.	131	273	
	4,808,152	02/1989	SIBALIS	604	20	
	4,813,437	03/1989	RAY	131	273	
	4,820,263	04/1989	SPEVAK ET AL.	604	20	
	4,821,740	04/1989	TACHIBANA ET AL.	604	20	
	4,838,273	06/1989	CARTMELL	600	392	
	4,865,582	09/1989	SIBALIS	604	20	
	4,907,606	03/1990	LILJA ET AL.	131	273	
	4,913,148	04/1990	DIETHELM			
	4,917,119	04/1990	POTTER ET AL.	131	273	
	4,919,648	04/1990	SIBALIS	604	20	
	4,922,901	05/1990	BROOKS ET AL.	128	203.26	
	4,931,046	06/1990	NEWMAN	604	20	
	4,942,883	07/1990	NEWMAN	604	20	
	4,950,229	08/1990	SAGE, JR.	604	20	
	4,953,565	09/1990	TACHIBANA ET AL.	604	20	
	4,957,480	09/1990	MORENINGS			
	4,979,938	12/1990	STEPHEN ET AL.			
	4,997,418	03/1991	DeMARTINI			
	5,002,527	03/1991	RELLER ET AL.			
	5,006,108	04/1991	LaPRADE	604	20	
	5,019,034	05/1991	WEAVER ET AL.	604	20	
	5,037,381	08/1991	BOCK ET AL.			
	5,042,975	08/1991	CHIEN ET AL.			
	5,047,007	09/1991	McNICHOLS ET AL.	604	20	
	5,053,001	10/1991	RELLER ET AL.	604	20	
	5,060,671	10/1991	COUNTS ET AL.	131	329	

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

3763

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,090,402	02/1992	BAZIN ET AL.			
	5,115,805	05/1992	BOMMANNAN ET AL.			
	5,133,352	07/1992	LATHROP ET AL.			
	5,135,478	08/1992	SIBALIS			
	5,135,479	08/1992	SIBALIS ET AL.	604	20	
	5,147,291	09/1992	CUKIER	604	22	
	5,160,316	11/1992	HENLEY	604	20	
	5,162,042	11/1992	GYORY ET AL.			
	5,167,242	12/1992	TURNER ET AL.	131	273	
	5,169,384	12/1992	BOSNIAK ET AL.			
	5,171,215	12/1992	FLANAGAN	604	20	
	5,203,768	04/1993	HAAK ET AL.			
	5,250,022	10/1993	CHIEN ET AL.			
	5,254,081	10/1993	MAURER ET AL.	604	20	
	5,279,543	01/1994	GLIKFELD ET AL.			
	5,284,471	02/1994	SAGE, JR.			
	5,298,017	03/1994	THEEUWES ET AL.			
	5,310,404	05/1994	GYORY ET AL.			
	5,312,326	05/1994	MYERS ET AL.			
	5,314,502	05/1994	McNICHOLS ET AL.			
	5,331,979	07/1994	HENLEY			
	5,354,321	10/1994	BERGER			
	5,360,440	11/1994	ANDERSEN			
	5,362,307	11/1994	GUY ET AL.			
	5,362,308	11/1994	CHIEN ET AL.			
	5,374,241	12/1994	LLOYD ET AL.			
	5,374,242	12/1994	HAAK ET AL.			
	5,376,107	12/1994	INAGI ET AL.			
	5,391,195	02/1995	VAN GRONINGEN			
	5,395,310	03/1995	UNTEREKER ET AL.			
	5,413,590	05/1995	WILLIAMSON			
	5,415,629	05/1995	HENLEY			
	5,421,816	06/1995	LIPKOVKER			
	5,441,936	08/1995	HOUGHTEN ET AL.			
	5,443,441	08/1995	De CLAVIERE			
	5,458,569	10/1995	KIRK III ET AL.	604	20	
*Examiner			Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,464,387	11/1995	HAAK ET AL.			
	5,466,217	11/1995	MYERS ET AL.			
	5,470,349	11/1995	KLEDITSCH ET AL.			
	5,494,679	02/1996	SAGE, JR. ET AL.			
	5,501,705	03/1996	FAKHRI			
	5,514,167	05/1996	SMITH ET AL.			
	5,538,503	07/1996	HENLEY			
	5,540,669	07/1996	SAGE, JR. ET AL.	604	20	
	5,551,953	09/1996	LATTIN ET AL.			
	5,558,632	09/1996	LLOYD ET AL.			
	5,562,607	10/1996	GYORY			
	5,589,563	12/1996	WARD ET AL.			
	5,603,693	02/1997	FRENKEL ET AL.			
	5,607,461	03/1997	LATHROP			
	5,607,691	03/1997	HALE ET AL.			
	5,618,275	04/1997	BOCK			
	5,658,247	08/1997	HENLEY			
	5,667,487	09/1997	HENLEY			
	5,668,170	09/1997	GYORY			
	5,676,648	10/1997	HENLEY			
	5,678,273	10/1997	PORCELLI			
	5,688,233	11/1997	HOFMANN ET AL.			
	5,697,896	12/1997	McNICHOLS ET AL.			
	5,700,457	12/1997	DIXON			
	5,711,761	01/1998	UNTEREKER ET AL.			
	5,713,846	02/1998	BERNHARD ET AL.			
	5,722,397	03/1998	EPPSTEIN			
	5,725,817	03/1998	MILDER			
	5,733,255	03/1998	DINH ET AL.			
	5,755,750	05/1998	PETRUSKA ET AL.			
	5,788,666	08/1998	ATANASOSKA			
	5,794,774	08/1998	PORCELLI			
	5,795,321	08/1998	McARTHUR ET AL.			
	5,797,867	08/1998	GUERRARA ET AL.			
	5,830,175	11/1998	FLOWER			
	5,840,057	11/1998	ALOISI			

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,846,217	12/1998	BECK ET AL.			
	5,865,786	02/1999	SIBALIS ET AL.	604	20	
	5,879,323	03/1999	HENLEY			
	5,882,676	03/1999	LEE ET AL.			
	5,899,875	5/1999	MILLOT			
	5,899,876	05/1999	FLOWER	604	20	
	5,908,401	06/1999	HENLEY	604	20	
	5,911,319	06/1999	PORCELLI ET AL.			
	5,919,155	07/1999	LATTIN ET AL.	604	20	
	5,931,859	08/1999	BURKE			
	5,935,598	08/1999	SAGE ET AL.			
	5,954,684	09/1999	FLOWER ET AL.	604	20	
	5,961,482	10/1999	CHIEN ET AL.			
	5,961,483	10/1999	SAGE ET AL.			
	5,968,005	10/1999	TU			
	5,968,006	10/1999	HOFMANN			
	5,983,130	11/1999	PHIPPS ET AL.			
	6,004,309	12/1999	PHIPPS			
	6,004,547	12/1999	ROWE ET AL.			
	6,006,130	12/1999	HIGO ET AL.			
	6,018,679	01/2000	DINH ET AL.			
	6,023,639	02/2000	HAKKY ET AL.			
	6,032,073	02/2000	EFFENHAUSER			
	6,038,485	03/2000	AXELGAARD			
	6,041,252	03/2000	WALKER ET AL.			
	6,041,253	03/2000	KOST ET AL.			
	6,048,545	04/2000	KELLER ET AL.			
	6,057,374	05/2000	HUNTINGTON ET AL.			
	6,101,411	08/2000	NEWSOME			
	6,148,231	11/2000	HENLEY	604	20	
	6,148,232	11/2000	AVRAHAMI	604	20	
	6,167,302	12/2000	MILLOT			
	6,385,487 B1	05/2002	HENLEY	604	20	
	6,477,410	11/2002	HENLEY ET AL			

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

FOREIGN PATENT DOCUMENTS

							TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO		
OE 0,232,642	03/1964	AT	604	20				
EP 617979 A1	10/1994	EPO						
FR 1,445,703	06/1966	FR	604	20				
FR 2 513 129	03/1983	FR						
GB 0,299,553	11/1928	GB	604	20				
EP 0230749	08/1987	EPO	604	20				
EP 0309093 A1	03/1989	EPO	604	20				
3-170172	07/1991	JP						X
WO 90/06153	06/1990	PCT			X			
SU654254	03/1979	U.S.S.R.						X
SU931191	05/1982	U.S.S.R.						X
SU1003853	03/1983	U.S.S.R.						X
08571	08/1990	WIPO	604	20				X
03790	03/1993	WIPO	604	20				
07269	12/1986	WIPO	604	20				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	"Iontophoretic Treatment of Oral Herpes," Henley et al.; Laryngoscope, Vol. 94, No. 1, pp. 118-121, January 1984
	"Iontophoretic Application of Idoxuridine for Recurrent Herpes Labialis: Report of Preliminary Chemical Trials," Gangarosa et al.; Meth. And Find. Exptl. Clin. Pharmacol. 1(2), pp. 105-109 (1979)
	"Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis," Gangarosa et al.; The Journal of Infectious Diseases, Vol. 154, No. 6, pp. 930-934, December 1986
	"The Natural History of Recurrent Herpes Simplex Labialis," Spruance et al.; The New England Journal of Medicine, Vol. 297, No. 2, pp. 69-75, July 14, 1977
	"Infection with Herpes-Simplex Viruses 1 and 2," Nahmias et al.; The New England Journal of Medicine, pp. 667-674, September 27, 1973
	"Anesthesia of the Human Tympanic Membrane by Iontophoresis of a Local Anesthetic," Comeau et al.; The Laryngoscope, 88:1978, pp. 277-285
	"Iontophoretic Application of Drugs," Waud, J. Appl. Physiol. 23(1), 1967, pp. 128-130
	"Antibiotic Iontophoresis in the Treatment of Ear Chondritis," LaForest et al., Physical Therapy, Vol. 58, No. 1, January 1978, pp. 32-34
	"The Quantity and Distribution of Radiolabeled Dexamethasone Delivered to Tissue by Iontophoresis," Glass et al.; International Journal of Dermatology, Vol. 19, November 1980, pp. 519-525
	"Iontophoretic Application of Antiviral Chemotherapeutic Agents," Hill et al., Annals New York Academy of Sciences, pp. 604-612
	"Ocular Iontophoresis," Hill et al. Paper, Louisiana State University Medical Center, School of Medicine, New Orleans, Louisiana, pp. 331-354

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		"Iontophoretic Application of Adenine Arabinoside Monophosphate to Herpes Simplex Virus Type 1-Infected Hairless Mouse Skin," Park et al.; Antimicrobial Agents and Chemotherapy, Vol. 14, No. 4, Oct., 1978, pp. 605-608
		"Iontophoresis: Applications in Transdermal Medication Delivery," Costello et al.; Physical Therapy, Vol. 75, No. 6, pp. 104/554-113/563, June 1995
		"Physical Enhancement of Dermatologic Drug Delivery: Iontophoresis and Phonophoresis, Kassan et al., Journal of the American Academy of Dermatology, April 1996, pp. 657-666
		"Iontophoresis and Herpes Labialis," Boxhall et al.; The Medical Journal of Australia, May 26, 1984, pp. 686-687
		"Iontophoresis: A Method of Antibiotic Administration in the Burn Patient," Rapperport et al., Plastic and Reconstructive Surgery, 1965, Vol. 36, No. 5, pp. 547-552
		"Iontophoresis for Enhancing Penetration of Dermatologic and Antiviral Drugs," Gangarosa et al., Journal of Dermatology, Vol. 22, No. 11, pp. 865-875, November 1995
		"Iontophoretic Treatment of Herpetic Whitlow," Gangarosa et al., Arch. Phys. Med. Rehabil., Vol. 70, pp. 336-340 April 1989
		"Iontophoretic Application of Antiviral Drugs," Gangarosa et al., Proceedings of an International Symposium held in Tokushima City, Japan, pp. 201-204, July 27-30, 1981
		"Iontophoretic Application of Adenine Arabinoside Monophosphate for the Treatment of Herpes Simplex Virus Type 2 Skin Infections in Hairless Mice," Gangarosa, The Journal of Infectious Diseases, Vol. 140, No. 6, pp. 1014, December 1979
		"Effect of Iontophoretic and Topical Application of Antiviral Agents in Treatment of Experimental HSV-1 Keratitis in Rabbits," Kwon et al., Investigative Ophthalmology & Visual Science, Vol. 18, No. 9, pp. 984-988, September, 1979
		"Acyclovir and Vidarabine Monophosphate: Comparison of Iontophoretic and Intravenous Administration for the Treatment of HSV-1 Stromal Keratitis," Hill et al., The American Journal of Medicine, Acyclovir Symposium, pp. 300-304
		"Thymine Arabinoside (Ara-T) Topical and Iontophoretic Applications for Herpes Simplex Virus Type 1 and Type 2 Skin Infections in Hairless Mice," Hill et al., Meth. And Find. Exptl. Clin. Pharmacol. 6(1), pp. 17-20, 1984
		"Iontophoresis Enhances the Transport of Acyclovir Through Nude Mouse Skin by Electropulsion and Electroosmosis," Volpato et al., Pharmaceutical Research, Vol. 12, No. 11, pp. 1623-1627, 1995
		"Early Application of Topical 15% Idoxuridine n Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial," Spruance et al., The Journal of Infectious Diseases, 1990; Vol. 161; pp. 191-197
		"Iontophoresis for Surface Local Anesthesia," Gangarosa, JADA, Vol. 88, pp. 125-128, January 1974
		"Conductivity of Drugs Used for Iontophoresis," Gangarosa et al., Journal of Pharmaceutical Sciences, Vol. 67, No. 10, pp. 1439-1443, October, 1978
		"A Pilot Study of Iontophoretic Cisplatin Chemotherapy of Basal and Squamous Cell Carcinomas of the Skin," Chang et al., Arch. Dermatol., Vol. 129, pp. 425-427, April 1993
		"How Modern Iontophoresis Can Improve Your Practice," Gangarosa et al., (Quintessence International) Oral Surgery, No. 10, Report 2135, October 1982, pp. 1027-1038
		"Postherpetic Neuralgia," Baron et al., Brain (1993), 116, pp. 1477-1496

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3589-56

APPLICANT

HENLEY et al

(Use several sheets if necessary)

FILING DATE

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		"Iontophoretic Assistance of 5-Iodo-2'-Deoxyuridine Penetration into Neonatal Mouse Skin and Effects of DNA Synthesis," Gangarosa et al., Society for Experimental Biology and Medicine, pp. 439-443, 1977
		"Electrophoretic Evaluation of the Mobility of Drugs Suitable for Iontophoresis," Kamath et al., Meth. Find. Exp. Clin. Pharmacol., 1995, 17(4): pp. 227-232
		"Transdermal Drug Delivery by Passive Diffusion and Iontophoresis: A Review," Singh et al., Medicinal Research Reviews, Vol. 13, No. 5, 1993, pp. 569-621
		"Iontophoresis: Electropulsion and Electroosmosis," Guy et al., Journal of Controlled Release 64 (2000) 129-132
		"Treatment of Common Cutaneous Herpes Simplex Virus Infections," Emmert, American Family Physician, Vol. 61, No. 6, March 15, 2000, pp. 1697-1704
		"Gelatin-stabilised Microemulsion-Based Oranogels: Rheology and Application in Iontophoretic Transdermal Drug Delivery," Kantaria et al., Journal of Controlled Release 60 (1999) 355-365
		"Electropulsion Versus Electroosmosis: Effect of pH on the Iontophoretic Flux of 5-Fluorouracil," Merino et al., Pharmaceutical Research, Vol. 16, No. 6 (1999)
		"Azelaic Acid: Potential as a General Antitumoural Agent," Breathnach, Medical Hypotheses (1999) 52(3) 221-226
		"Treatment of Mucocutaneous Herpes Simplex Virus Infections Unresponsive to Acyclovir with Topical Foscarnet Cream in AIDS Patients: A Phase I/II Study," Javaly et al., Journal of Acquired Immune Deficiency Syndromes 21:301-306
		"Efficacy and Safety of Azelaic Acid and Glycolic Acid Combination Therapy Compared with Tretinoin Therapy for Acne," Spellman et al., Clinical Therapeutics, Vol. 20, No. 4, 1998, pp. 711-721
		"Passive Versus Electrotransport-Facilitated Transdermal Absorption of Ketorolac," Park et al., Clinical Pharmacology & Therapeutics, Vol. 63, No. 3, pp. 303-315
		"Soriudine Versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial," Gnann et al., Antimicrobial Agents and Chemotherapy, Vol. 42, No. 5, May 1998, pp. 1139-1145
		"Azelaic Acid 20% Cream (AZELEX®) and the Medical Management of Acne Vulgaris," Gibson, Dermatology Nursing, Vol. 9, No. 5, pp. 339-344
		"Sorivudine: A Promising Drug for the Treatment of Varicella-Zoster Virus Infection," Whitley, Neurology 1995; 45 (Supp. 8), pp. S73-S75
		"Antiherpesviral and Anticellular Effects of 1-β-D-Arabinofuranosyl-E-5-(2-Halogenovinyl) Uracils," Machida et al., Antimicrobial Agents and Chemotherapy, July 1981, pp. 47-52
		"Herpes Simplex," American Academy of Dermatology, 1987, Revised 1991, 1993
		"Common Cold' Virus is Near," Haney, The Associated Press, January 15, 2000
		"New Medicines Move to Eradicate Acne," Hemphill, The New York Times, February 29, 2000
		"Warts," American Academy of Dermatology, American Academy of Dermatology, 1997, Revised 1991, 1993
		"Psoriasis," American Academy of Dermatology, 1994
		"Eczema/Atopic Dermatitis," American Academy of Dermatology, 1987, Revised 1991, 1993, 1995
		"Skin Cancer: An Undeclared Epidemic," American Academy of Dermatology, 1988, Revised 1989, 1993, 1994

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)